Hidiroglu, MeteUguz, EmrahOzerdem, GokhanYildiz, EsinBerkan, Ocal2019-07-272019-07-282019-07-272019-07-2820141301-5680https://dx.doi.org/10.5606/tgkdc.dergisi.2014.8304https://hdl.handle.net/20.500.12418/8442Background: This study aims to elucidate whether pentoxifylline, iloprost and cilostazol mitigates acute lung injury induced by lower limb ischemia-reperfusion (I/R) and their protective effects cover cytokines. Methods: Forty rats were randomized into five groups: control (group 1), ischemia-reperfusion (group 2), pentoxifylline (group 3), iloprost (group 4), iloprost and cilostazol (group 5). All drugs were administered before ischemia. Samples were obtained for tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), and total sialic acid (TSA) assays. Findings of lung injury were examined. Results: Interleukin-6 and TNF levels were increased at 90 minutes and sustained elevated even after 240 minutes. In groups 3 and 4, IL-6 and TNF levels were significantly lower at 90, 180 and 240 minutes compared to group 2. At 180 minutes, TSA levels in groups 2, 3, 4 and 5 were significantly different from baseline and 90 minute levels. At this time point, TSA levels of group 2 and 3 were significantly higher compared to group 4 and 5. Conclusion: In this acute lung injury model induced by I/R of the lower limbs, pretreatment with pentoxifylline, iloprost and cilostazol significantly attenuated proinflammatory activities and parenchymal lung damage.en10.5606/tgkdc.dergisi.2014.8304info:eu-repo/semantics/closedAccessCilostazoliloprostischemia-reperfusion injurylung injurypentoxifyllineArticle2211441382-s2.0-84897727840Q3WOS:000330199000023Q4